PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »
Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.
Find out more »Keep up to date with latest news and analyses from PCSK9 inhibitor trials.
For expert analysis and insights
18th Virtual Closed Scientific Expert Meeting of the Editorial Board
Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention
Professor Alberto Zambon proposes a novel ‘fast to target’ paradigm for patients at very high cardiovascular risk.
Related content:
Lerodalcibep: What does LIBerate-HeFH tell us?
Professor Derick Raal discusses lerodalcibep data from the LIBerate-HeFH trial and explains what the results mean to practising clinicians.
Related content: